Optimization and impact of an evidence-based pre-audit prescription decision system in primary healthcare settings

优化和评估基于证据的处方决策预审核系统在基层医疗机构中的影响

阅读:1

Abstract

OBJECTIVE: Analyze the operation mode of the prescription pre-audit intelligent decision system in a county-level hospital, evaluate its intervention effects on outpatient and emergency operations, thus providing references for similar hospitals to carry out pre-audit intelligent decision system and promote rational drug use. METHODS: Utilizing evidence-based approaches, system rule modifications have been refined and synergized with AI-driven decision-making analytics to examine the operational framework of pre-audit prescription decision system. Additionally, retrospectively analyze the types and levels of problems triggered by outpatient and emergency prescriptions from October 2022 to August 2023, as well as the rationality of prescriptions in the system. RESULTS: According to the clinical operation of the hospital, problems triggered by unreasonable prescriptions have been finely classified into different levels according to the severity of prescription problems. From October 2022 to August 2023, the number of prescriptions triggering issues such as indications, dosage, special populations, compatibility, administration, and contraindications showed a decreasing trend compared with October 2022 before the intervention. For example, the number of prescriptions with unreasonable routes of administration decreased from 1,745 to 20, and the number of contraindicated prescriptions decreased from 1,399 to 16. The prescriptions triggering Level 5 alerts decreased from 5.609% to 1.793% and the prescription compliance rate increased from 92.20% to 95.98%. CONCLUSION: The prescription pre-audit intelligent decision system enhances patient safety and promotes rational drug use. However, the system requires fine-tuning and continuous improvement of the system rule library to effectively validate prescriptions and improve prescription accuracy. In the future, integrating big data, artificial intelligence and other technologies for secondary system development will be a model worthy of consideration. In addition, promoting this system to medical federation to establish a regional prescription review model will further promote the high-quality development of pharmaceutical services.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。